Benchmark Reiterates Speculative Buy on Biolase, Maintains $0.4 Price Target
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Bruce Jackson has reiterated a Speculative Buy rating on Biolase (OTC:BIOL) and maintained a price target of $0.4.
August 12, 2024 | 5:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Benchmark analyst Bruce Jackson has reiterated a Speculative Buy rating on Biolase and maintained a price target of $0.4.
The reiteration of a Speculative Buy rating and the maintenance of a price target by a reputable analyst can positively influence investor sentiment and potentially drive short-term price appreciation.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100